fotoknips-shutterstock-com-1
fotoknips / Shutterstock.com
8 October 2015Big PharmaNatalia Wegner-Cribbs and Daniel Wise

A clearer picture for SPCs?

On October 6, the Court of Justice of the European Union (CJEU) delivered its judgment in case C-471/14. It clarified that the term of a supplementary protection certificate (SPC) is determined with reference to the date on which a marketing authorisation is notified to that applicant. This means that in many cases SPC owners that do not already benefit from the maximum five-year term will get some additional term for their products, although it remains to be seen how and to what extent the judgment will be implemented from a practical point of view by the various national patent offices. The judgment may also have implications for aspects of SPC law other than the SPC term, on which the CJEU did not provide any guidance.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
6 October 2015   The Court of Justice of the European Union (CJEU) has ended the uncertainty over the term of supplementary protection certificates (SPCs) by ruling that they begin once a party is notified of a marketing authorisation for a drug.
Big Pharma
25 August 2016   In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates.

More on this story

Europe
6 October 2015   The Court of Justice of the European Union (CJEU) has ended the uncertainty over the term of supplementary protection certificates (SPCs) by ruling that they begin once a party is notified of a marketing authorisation for a drug.
Big Pharma
25 August 2016   In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates.

More on this story

Europe
6 October 2015   The Court of Justice of the European Union (CJEU) has ended the uncertainty over the term of supplementary protection certificates (SPCs) by ruling that they begin once a party is notified of a marketing authorisation for a drug.
Big Pharma
25 August 2016   In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates.